Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Unesbulin (PTC596) in Advanced Solid Tumors
NCT02404480Phase 1Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Jan 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of unesbulin in solid tumor (7 arms), sponsored by PTC Therapeutics, Inc. Primary endpoint: Dose-limiting toxicities at 28 days. Started Jan 2016; status: completed.
02
Drugs
unesbulin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02404480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02404480.